Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of AlloVir, Inc. related to misrepresentation of the company's posoleucel Phase 3 studies [1] Group 1: Allegations Against AlloVir - AlloVir insiders allegedly caused the company to misrepresent or fail to disclose that the posoleucel Phase 3 studies were unlikely to meet their primary endpoints [1] - It is suggested that the company is likely to discontinue the posoleucel Phase 3 studies as a result of the aforementioned issues [1] - The company is accused of overstating the efficacy and clinical and/or commercial prospects of posoleucel, leading to materially false and misleading public statements [1]